key: cord-0982465-8xluzhzz
authors: Kayaaslan, Bircan; Eser, Fatma; Kaya Kalem, Ayşe; Bilgic, Zeynep; Asilturk, Dilek; Hasanoglu, Imran; Ayhan, Muge; Tezer Tekce, Yasemin; Erdem, Deniz; Turan, Sema; Mumcuoglu, Ipek; Guner, Rahmet
title: Characteristics of candidemia in COVID‐19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non‐COVID‐19 patients
date: 2021-06-16
journal: Mycoses
DOI: 10.1111/myc.13332
sha: d29106ca64481a10ffdcbc9e155ce09c2208407f
doc_id: 982465
cord_uid: 8xluzhzz

Severe COVID‐19 patients in ICU are at high risk for candidemia due to exposure to multiple risk factors for candidemia. We aimed to compare the incidence of candidemia in ICU patients with and without COVID‐19, and to investigate epidemiologic and clinical characteristics of candidemia patients and risk factors for mortality in candidemia patients. This retrospective study was conducted in patients followed in the ICUs of Ankara City Hospital for 2 years, divided into pre‐pandemic and pandemic periods. The incidence (event per 1000 patient‐days) and epidemiology of candidemia, clinical and laboratory characteristics of patients were compared in COVID‐19 and non‐COVID‐19 groups. Candidemia incidence was higher in the COVID‐19 group (2.16, 95% CI 1.77–2.60) than the non‐COVID‐19 group (1.06, 95% CI 0.89–0.125) (p < .001). A total of 236 candidemia episodes (105 in COVID‐19 patients and 131 in non‐COVID‐19 patients) were detected during the study periods. COVID‐19 cases had a higher rate of corticosteroid use (63.8% vs. 9.9%, p < .001). Epidemiology of candidemia and antifungal susceptibility were similar. Candidemia developed 2 weeks earlier in COVID‐19 groups and resulted in higher mortality (92.5% vs. 79.4%, p .005). One‐third of candidemia patients died before receiving any antifungal treatment, and this rate was higher in the COVID‐19 group. In multivariate logistic regression analysis, corticosteroid use, presence of sepsis and age older than 65 years were independent risk factors for mortality in candidemia patients. Candidemia with high mortality is a more serious problem for COVID‐19 patients due to its increased incidence, earlier occurrence and a higher rate of mortality.

This retrospective study was conducted in Ankara City Hospital, the main pandemic centre and a tertiary hospital in the capital. The authors confirm their adherence to the ethical policies of the journal, as noted on the journal's author guidelines page. Ethical approval was obtained from Ankara City Hospital Ethical Committee 1. All patients older than 18 years followed with the diagnosis of candidemia in ICUs located in two buildings (neurology-orthopaedic and cardio- The diagnosis of COVID-19 was made with polymerase chain reaction (PCR) for SARS-CoV-2 and/or the presence of typical findings for COVID-19 on computed tomography with a positive antibody test. Candidemia was identified as the detection of one or more Candida species in at least one blood culture in patients who have findings compatible with infection. Each patient was included only once in the study. BacT/Alert (bioMerieux) automated blood culture system was used for monitoring blood culture bottles. Yeasts were identified at species level by using VitekMS (bioMerieux) device and MALDI-TOF MS method. Sensitivity tests were evaluated with Vitek2 (bioMerieux) automated system. Candida colonisation index was calculated as the ratio of the number of distinct body sites colonised with Candida strain over the total number of distinct body sites cultures tested (threshold 0.5). 11 Candida score was calculated as follows: multifocal Candida species colonisation (1 point), surgery (1 point), total parenteral nutrition (1 point), sepsis (2 points).

Variables were encoded as 0 if it was absent and as valid points if it was present. The threshold was 2.5 points for high risk for candidemia. 12 In order to evaluate whether there is a change in the incidence of candidemia during the pandemic period, we compared COVID-19 patients followed up in a one-year period (pandemic period) and non-COVID-19 patients followed up in two-year period (prepandemic and pandemic periods) in terms of candidemia incidence rate (candidemia episode per 1000 patient-days) and the percentages of candidemia (episode per 100 patients). We also compared candidemia cases with and without COVID-19 in terms of clinical characteristics, risk factors for candidemia, candidemia colonisation index, candidemia score, laboratory parameters on the day of candidemia, Candida species, and antifungal susceptibilities, antifungal treatments and patients' outcomes including duration of ICU stay and mortality. Risk factors for mortality in patients with candidemia were investigated. (9), Escherichia coli (7) and others (10) . In this study, we evaluated a large number of patients who 

White blood cell, cells ×10 9 /L 11.6 (7. Note: Data are presented as n (%) unless noted otherwise. a IQR, Interquartile range (25% and 75%). Another notable result of our study is that one-third of all patients with candidemia in the study had died before receiving any antifungal treatment, and this rate was higher in COVID-19 group.

Some of the remaining patients with COVID-19 were able to receive antifungal treatment for shorter than proper treatment dura- We also demonstrated that corticosteroid treatment is a mortalityassociated factor in patients with candidemia despite its benefits in severe COVID-19 patients. In a large series with 842 patients with candidemia, corticosteroid use was found to be associated with treatment failure and poor survival. 21 In another large series study, corticosteroid use differed between surviving and deceased patients, but was not an independent risk factor in multivariate analysis. 20 Appropriate and non-delayed antifungal therapy is crucial for the treatment of candidemia. 19 In this study, some of the patients were unable to receive any antifungal agents, and some had received for 3 days or shorter. However, we did not demonstrate an independent association between short treatment duration and mortality in multivariate analysis. Delaying antifungal treatment until the obtainment of positive blood culture was reported as an independent risk factor for high mortality. 23 

The authors have no conflicts of interest to declare. 

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

https://orcid.org/0000-0001-5225-8319

A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality

Hospital-acquired infections

Invasive candidiasis

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Dexamethasone in hospitalized patients with Covid-19

Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial

Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial

Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic

Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls

Is the frequency of Candidemia increasing in COVID-19 patients receiving corticosteroids?

Candida colonization and subsequent infections in critically ill surgical patients

Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization

Glucocorticoids and invasive fungal infections

Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis

COVID-19 associated invasive candidiasis

COVID-19-associated candidiasis (CAC): an underestimated complication in the absence of immunological predispositions?

Candidemia in the critically ill: initial therapy and outcome in mechanically ventilated patients

Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain

Mortality and risk factor analysis for Candida blood stream infection: a multicenter study

Epidemiology and predictors of a poor outcome in elderly patients with candidemia

Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials

Risk factors for candidemia mortality in hospitalized children

Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality

Characteristics of candidemia in COVID-19 patients

increased incidence, earlier occurrence and higher mortality rates compared to non-COVID-19 patients